Agilent Technologies, Inc. (A)
| Market Cap | 38.41B |
| Revenue (ttm) | 7.23B |
| Net Income (ttm) | 1.41B |
| Shares Out | 282.43M |
| EPS (ttm) | 4.98 |
| PE Ratio | 27.29 |
| Forward PE | 21.55 |
| Dividend | $1.02 (0.75%) |
| Ex-Dividend Date | Jun 30, 2026 |
| Volume | 3,133,339 |
| Open | 135.17 |
| Previous Close | 135.51 |
| Day's Range | 134.98 - 137.50 |
| 52-Week Range | 108.35 - 160.27 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 160.33 (+17.88%) |
| Earnings Date | May 27, 2026 |
About A
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnosti... [Read more]
Financial Performance
In fiscal year 2025, Agilent Technologies's revenue was $6.95 billion, an increase of 6.73% compared to the previous year's $6.51 billion. Earnings were $1.30 billion, an increase of 1.09%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for A stock is "Buy." The 12-month stock price target is $160.33, which is an increase of 17.88% from the latest price.
News
Agilent resumed with an Outperform at Bernstein
Bernstein analyst Eve Burstein resumed coverage of Agilent (A) with an Outperform rating and $155 price target following a return from maternity leave. “Many things” are going right for the…
Agilent completes acquisition of Biocare Medical
Agilent (A) Technologies announced the completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners an...
Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies
Denver, CO and London, UK – 25 June 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partn...
Agilent Completes Acquisition of Biocare Medical
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clini...
UMH PROPERTIES, INC. WELCOMES THE 21ST CENTURY ROAD TO HOUSING ACT: A MAJOR BOOST FOR AFFORDABLE MANUFACTURED HOUSING
Freehold, NJ, June 24, 2026 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, today expressed stron...
Tradeweb Announces Date for Second Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, will release financial results for the second quarter of 2026 on Thursday, Ju...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 7, 2026 in BitGo Holdings, Inc. Lawsuit - BTGO
Alert: Claims Focus on Alleged Misrepresentations About BitGo's Digital Asset Sales Margin Compression and Bitcoin Treasury Losses NEW YORK, June 11, 2026 /PRNewswire/ -- SueWallSt reminds purchasers ...
Agilent initiated with a Neutral at Piper Sandler
Piper Sandler analyst David Westenberg initiated coverage of Agilent (A) with a Neutral rating and $150 price target The firm launched coverage of the life science tools sector with a…
Agilent Technologies Transcript: Jefferies Global Healthcare Conference 2026
Strong revenue and margin growth were driven by innovation, tech refresh cycles, and robust performance in diagnostics, semiconductors, and advanced materials. AI and digital initiatives, new product launches, and strategic M&A are expected to sustain momentum, with significant growth anticipated in China and ATD by 2027.
Agilent announces collaboration with OpenAI, BCG
Agilent (A) Technologies announced a collaboration with OpenAI and Boston Consulting Group, BCG, to accelerate the deployment of artificial intelligence, AI, across the company’s products, operations,...
Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate th...
Agilent price target lowered to $165 from $180 at HSBC
HSBC analyst Sidharth Sahoo lowered the firm’s price target on Agilent (A) to $165 from $180 and keeps a Buy rating on the shares. The firm says market expectations on…
Agilent receives FDA approval for expanded use of PD-L1 IHC 22C3 pharmDx
The company states: “Agilent (A) Technologies announced that the FDA has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to…
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code...
Agilent price target raised to $155 from $145 at BofA
BofA analyst Michael Ryskin raised the firm’s price target on Agilent (A) to $155 from $145 and keeps a Buy rating on the shares. Diagnostic tools have rallied almost 10%…
Agilent assumed with a Peer Perform at Wolfe Research
Wolfe Research assumed coverage of Agilent (A) with a Peer Perform rating. The company’s most recent quarter was a “small speed up with more thematic good guys than bad”, its…
Agilent initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of Agilent (A) with a Peer Perform rating and $130-$140 price target range. The company’s most recent quarter was a “small speed up with more thematic…
Agilent price target raised to $155 from $153 at RBC Capital
RBC Capital raised the firm’s price target on Agilent (A) to $155 from $153 and keeps an Outperform rating on the shares after its Q2 earnings beat. Agilent exceeded Street…
Agilent price target raised to $155 from $147 at TD Cowen
TD Cowen raised the firm’s price target on Agilent (A) to $155 from $147 and keeps a Buy rating on the shares. The firm updated its model following strong Q2…
Agilent introduces OpenLab Sync lab execution system
Agilent (A) Technologies announced the introduction of OpenLab Sync, a new Lab Execution System that enables laboratories to digitally connect scientific workflows from method design through execution...
Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally conn...
Agilent price target raised to $158 from $156 at Baird
Baird raised the firm’s price target on Agilent (A) to $158 from $156 and keeps an Outperform rating on the shares. The firm updated its model following the announcement of…
Agilent upgraded to Buy at BofA after ‘solid’ beat in Q2
As previously reported, BofA upgraded Agilent (A) to Buy from Neutral with a price target of $145, down from $150, following what the firm calls a “solid” fiscal Q2 beat.
Agilent price target lowered to $160 from $165 at Wells Fargo
Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Agilent (A) to $160 from $165 and keeps an Overweight rating on the shares. The firm notes the company…
Agilent Technologies Earnings Call Transcript: Q2 2026
Q2 delivered strong revenue, margin, and EPS growth, exceeding guidance across all metrics. Robust performance was broad-based, with standout gains in diagnostics, advanced materials, and forensics, while operational improvements and innovation drove margin expansion and raised full-year guidance.